Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Venipharm Gets European Enoxaparin Nod

Executive Summary

Venipharm has received approval for its enoxaparin through the European decentralized procedure. The product was developed in collaboration with China’s Nanjing King-Friend Biochemical Pharmaceutical.

You may also be interested in...



China’s Nanjing King-Friend Takes Control Of US Injectables Specialist Meitheal

China’s Nanjing King-Friend Biochemical Pharmaceutical has taken a majority stake in US generic injectables specialist Meitheal Pharmaceuticals.

Rovi Rolls Out Enoxaparin In Portugal As It Prepares For Teriparatide

Rovi has started to market its enoxaparin biosimilar directly in Portugal as the Spanish company prepares to market teriparatide in its domestic market through a tie-up with Teva.

Rovi gets enoxaparin in Spain and France

Laboratorios Farmacéuticos Rovi has expanded the presence of its enoxaparin in Europe, after launching a rival to Sanofi’s Lovenox under its own name in Spain and introducing its Crusia version in France via a partnership with Biogaran.

Topics

UsernamePublicRestriction

Register

GB140144

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel